ZIOPHARM Oncology, Inc

(NASDAQ:ZIOP)

Latest On ZIOPHARM Oncology, Inc (ZIOP):

Date/Time Type Description Signal Details
2022-01-26 13:04 ESTNewsZIOPHARM changes name to Alaunos Therapeutics; shares up 5% premarketN/A
2021-12-13 10:00 ESTNewsWarning: ZIOP is at high risk of performing badlyN/A
2021-11-08 21:44 ESTNewsZIOPHARM Oncology EPS beats by $0.02N/A
2021-11-08 21:43 ESTNewsZIOPHARM Oncology, Inc. (ZIOP) CEO Kevin Boyle on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-08 01:28 ESTNewsZIOPHARM Oncology Q3 2021 Earnings PreviewN/A
2021-10-06 21:31 ESTNewsZIOP is at high risk of performing badlyN/A
2021-09-28 05:20 ESTNewsWarning: ZIOP has been downgraded to Very BearishN/A
2021-09-28 05:00 ESTNewsZiopharm Oncology cuts half its workforce to extend cash runway; shares down 9%N/A
2021-09-22 11:21 ESTNewsWarning: ZIOP has been downgraded to Very Bearish.N/A
2021-09-07 23:00 ESTNewsZIOPHARM Oncology gains over a third, the most in over six years after insider purchaseN/A
2021-08-30 21:52 ESTNewsNew CEO at Ziopharm Oncology, shares up 3%N/A
2021-08-10 14:43 ESTNewsZIOPHARM Oncology's (ZIOP) CEO Heidi Hagen on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-10 14:42 ESTNewsZIOPHARM Oncology, Inc. 2021 Q2 - Results - Earnings Call PresentationN/A
2021-08-10 14:42 ESTNewsZIOPHARM Oncology reports Q2 resultsN/A
2021-08-10 14:41 ESTNewsZIOPHARM down 11% on Q2 2021 earnings results, analyst downgradeN/A
2021-07-22 09:25 ESTNewsZIOPHARM records sharpest gain in nearly four monthsN/A
2021-07-22 09:18 ESTNewsZiopharm: Waiting On FYE 2021 For Further Clinical Data On TCR-T/CAR-T TherapiesN/A
2021-05-07 18:06 ESTNewsZIOPHARM Oncology, Inc.'s (ZIOP) Interim CEO Heidi Hagen on Q1 2021 Results - Earnings Call TranscriptN/A
2021-05-07 18:05 ESTNewsZIOPHARM Oncology, Inc. 2021 Q1 - Results - Earnings Call PresentationN/A
2021-05-06 21:56 ESTNewsZIOPHARM Oncology EPS beats by $0.01N/A
2021-04-19 19:44 ESTNewsZiopharm infuses first patient in CD19 RPM CAR-T early-stage trialN/A
2021-04-09 12:54 ESTNewsZiopharm Oncology signs consulting agreement with former CEON/A
2021-03-22 17:14 ESTNewsZooming In On Ziopharm OncologyN/A
2021-03-16 22:28 ESTAnalyst RatingThe Analyst Target Price has decreased from $6 to $5.67.Neutral
2021-03-12 14:23 ESTNewsT-cell receptor therapies could benefit Ziopharm Oncology, but will take timeN/A
2021-03-02 08:56 ESTAnalyst RatingThe Analyst Target Price has increased from $5.93 to $6.Buy
2021-03-01 21:02 ESTFinancialsCompany financials have been released.Neutral
2021-03-01 04:59 ESTEarnings EstimateAn EPS average of -$0.46 is estimated for the 2022 year.Sell
2021-03-01 04:59 ESTEarnings EstimateAn EPS average of -$0.11 is estimated for the quarter ending on June 30, 2021.N/A
2021-02-28 18:25 ESTFinancialsCompany financials have been released.Neutral
2021-02-27 21:05 ESTFinancialsCompany financials have been released.Neutral
2021-02-26 09:43 ESTNewsZIOPHARM Oncology, Inc. (ZIOP) CEO Laurence Cooper on Q4 2020 Results - Earnings Call TranscriptN/A
2021-02-26 09:43 ESTNewsZIOPHARM Oncology, Inc. 2020 Q4 - Results - Earnings Call PresentationN/A
2021-02-05 17:22 ESTNewsZiopharm extends rally after naming activist to the boardN/A
2021-01-15 17:36 ESTNewsZiopharm Oncology (ZIOP) Presents at J.P. Morgan Healthcare Conference 2021 - SlideshowN/A
2021-01-15 03:04 ESTNewsZiopharm gains after electing venture capital partner as ChairmanN/A
2021-01-14 11:02 ESTNewsZioPharm highlights upcoming catalysts, says current cash runway into mid-2022N/A
2020-12-21 17:25 ESTNewsZiopharm Oncology to test non-viral CAR-T in leukemia and lymphoma patientsN/A
2020-12-18 02:27 ESTNewsActivist holder wins Ziopharm Oncology board seatsN/A
2020-12-15 03:25 ESTNewsZiopharm Oncology CFO to step downN/A
2020-11-26 22:12 ESTFinancialsCompany financials have been released.Neutral
2020-11-21 08:09 ESTNewsZiopharm says WaterMill’s nominees lack experience, White Rock backs proposal on board reconstitutionN/A
2020-11-21 08:08 ESTNewsZiopharm Oncology (ZIOP) Investor Presentation - SlideshowN/A
2020-11-08 09:13 ESTFinancialsCompany financials have been released.Neutral
2020-11-08 01:23 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 19:56 ESTNewsZIOPHARM Oncology, Inc. (ZIOP) CEO Laurence Cooper on Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-07 19:53 ESTNewsZIOPHARM Oncology, Inc. 2020 Q3 - Results - Earnings Call PresentationN/A
2020-11-07 17:39 ESTFinancialsCompany financials have been released.Neutral
2020-11-06 04:57 ESTEarnings EstimateAn EPS average of -$0.09 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-05 19:22 ESTNewsZIOPHARM Oncology Q3 Earnings PreviewN/A

About ZIOPHARM Oncology, Inc (ZIOP):

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

ZIOP Quotes by TradingView

See Advanced Chart

General

  • Name ZIOPHARM Oncology, Inc
  • Symbol ZIOP
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 103
  • Last Split Factor1:40
  • Last Split Date2005-08-24
  • Fiscal Year EndDecember
  • IPO Date2005-08-24
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://ziopharm.com
View More

Valuation

  • Trailing PE 4.35
  • Price/Book (Most Recent Quarter) 7.6
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.44
  • Next Year EPS Estimate -$0.47
  • Next Quarter EPS Estimate -$0.10
  • Return on Assets -39%
  • Return on Equity -73%
  • Earnings Per Share $0.58
  • Revenue Per Share $0
  • Gross Profit -52696000
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 880.13 million
  • EBITDA -53090000
  • Analyst Target Price $5.67
  • Book Value Per Share $0.58
View More

Share Statistics

  • Shares Outstanding 214.67 million
  • Shares Float 180.06 million
  • % Held by Insiders 656%
  • % Held by Institutions 55.19%
  • Shares Short 35.2 million
  • Shares Short Prior Month 33.94 million
  • Short Ratio 9.66
  • Short % of Float 18%
  • Short % of Shares Outstanding 16%
View More

Technicals

  • Beta 2.11
  • 52 Week High $5.95
  • 52 Week Low $2.06
  • 50 Day Moving Average 4.67
  • 200 Day Moving Average 3.24
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

ZIOPHARM Oncology, Inc (ZIOP) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

ZIOPHARM Oncology, Inc (ZIOP) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-25$N/A-$0.11-$0.10-10.78%
2020-09-302020-11-05$N/A-$0.10-$0.09-11.23%
2020-06-302020-08-06$N/A-$0.09-$0.091.53%
2020-03-312020-05-07$N/A-$0.09-$0.09-5.88%
2019-12-312020-03-02$N/A-$0.09-$0.08-13.78%
2019-09-302019-11-07$N/A-$0.43-$0.09-377.78%
2019-06-302019-08-08$N/A-$0.09-$0.08-10.29%
2019-03-312019-05-08$N/A-$0.08-$0.084.76%
2018-12-312019-03-05$146000$1.29-$0.111262.16%
2018-09-302018-11-09$N/A-$0.13-$0.11-14.34%
2018-06-302018-08-08$-146000-$0.12-$0.123.85%
2018-03-312018-05-10$146000-$0.15-$0.13-17.65%
2017-12-312018-03-01$1.6 million-$0.13-$0.143.7%
2017-09-302017-11-06$1.6 million-$0.13-$0.133.27%
2017-06-302017-07-31$1.6 million-$0.13-$0.131.44%
2017-03-312017-05-01$1.6 million-$0.15-$0.12-27.23%
2016-12-312017-02-16$1.6 million-$0.11-$0.111.79%
2016-09-302016-11-09$1.6 million-$0.11-$0.112.14%
2016-06-302016-08-09$1.7 million-$1.01-$0.11-861.9%
2016-03-312016-05-10$1.97 million-$0.09-$0.09-2.86%
2015-12-312016-02-24$1.92 million-$0.07-$0.07-2.79%
2015-09-302015-11-02$1.87 million-$0.14-$0.12-16.67%
2015-06-302015-08-10$272000-$0.11-$0.2556%
2015-03-312015-05-07$272000-$0.10-$0.1216.67%
2014-12-312015-02-26$340000-$0.09-$0.1435.71%
2014-09-302014-10-30$633000-$0.06-$0.1250%
2014-06-302014-08-07$200000-$0.06-$0.1250%
2014-03-312014-05-08$200000-$0.10-$0.100%
2013-12-312014-03-03$200000-$0.09-$0.1435.71%
2013-09-302013-10-22$200000-$0.20-$0.200%
2013-06-302013-08-08$200000-$0.22-$0.248.33%
2013-03-312013-05-07$200000-$0.15-$0.2744.44%
2012-12-312013-03-18$200000-$0.37-$0.29-27.59%
2012-09-302012-11-08$200000-$0.23-$0.2920.69%
2012-06-302012-08-02$200000-$0.30-$0.25-20%
2012-03-312012-05-03$200000-$0.32-$0.23-39.13%
2011-12-312012-02-29$267000-$0.19-$0.2626.92%
2011-09-302011-11-03$200000-$0.01-$0.2495.83%
2011-06-302011-08-01$200000-$0.16-$0.1915.79%
2011-03-312011-05-05$67000-$0.65-$0.13-400%
2010-12-312011-03-01$N/A-$0.25-$0.24-4.17%
2010-09-302010-11-04$N/A-$0.26-$0.14-85.71%
2010-06-302010-07-30$N/A$0.19-$0.12258.33%
2010-03-312010-04-30$N/A-$0.44-$0.10-340%
2009-12-312010-03-18$N/A-$0.14-$0.12-16.67%
2009-09-302009-11-11$N/A-$0.13
2009-06-302009-08-14$N/A-$0.11
2009-03-312009-05-15$N/A-$0.16
2008-12-312009-03-23$N/A-$0.21-$0.19-10.53%
2008-09-302008-10-30$N/A-$0.26-$0.260%
2008-06-302008-07-31$N/A-$0.31-$0.3613.89%
2008-03-312008-05-12$N/A-$0.41-$0.39-5.13%
2007-12-312008-02-21$N/A-$0.36-$0.397.69%
2007-09-302007-11-02$N/A-$0.35-$0.34-2.94%
2007-06-302007-08-13$N/A-$0.31-$0.27-14.81%
2007-03-312007-05-02$N/A-$0.29-$0.25-16%
2006-12-312007-02-13$N/A-$0.38-$0.36-5.56%
2006-09-302006-11-13$N/A-$0.23
2006-06-302006-08-14$N/A-$0.43
2006-03-312006-05-15$N/A-$0.44
2005-12-312005-12-31$N/A-$90.48
2005-09-302005-09-30$N/A-$0.77

ZIOPHARM Oncology, Inc (ZIOP) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

ZIOPHARM Oncology, Inc (ZIOP) Chart:

ZIOPHARM Oncology, Inc (ZIOP) News:

Below you will find a list of latest news for ZIOPHARM Oncology, Inc (ZIOP) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

ZIOPHARM Oncology, Inc (ZIOP) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

ZIOPHARM Oncology, Inc (ZIOP) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312520184639/0001193125-20-184639-index.htm
2019-02-19UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1107421/000000000019002609/0000000000-19-002609-index.htm
2019-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1107421/000021545719005720/0000215457-19-005720-index.htm
2020-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1107421/000083423720006746/0000834237-20-006746-index.htm
2020-10-16PREC14APreliminary proxy statements, contested solicitationshttps://www.sec.gov/Archives/edgar/data/1107421/000092189520002619/0000921895-20-002619-index.htm
2020-10-26PRRN14ANon-management revised preliminary proxy soliciting materials, contested and otherwisehttps://www.sec.gov/Archives/edgar/data/1107421/000092189520002699/0000921895-20-002699-index.htm
2020-10-28PRRN14ANon-management revised preliminary proxy soliciting materials, contested and otherwisehttps://www.sec.gov/Archives/edgar/data/1107421/000092189520002713/0000921895-20-002713-index.htm
2020-10-29PRRN14ANon-management revised preliminary proxy soliciting materials, contested and otherwisehttps://www.sec.gov/Archives/edgar/data/1107421/000092189520002726/0000921895-20-002726-index.htm
2020-10-30DEFC14ADefinitive proxy statement, contested solicitationshttps://www.sec.gov/Archives/edgar/data/1107421/000092189520002751/0000921895-20-002751-index.htm
2020-11-02DFAN14AAdditional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1107421/000092189520002762/0000921895-20-002762-index.htm
2020-11-04DFRN14ARevised definitive proxy statement filed by non-managementhttps://www.sec.gov/Archives/edgar/data/1107421/000092189520002790/0000921895-20-002790-index.htm
2020-11-05DFAN14AAdditional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1107421/000092189520002806/0000921895-20-002806-index.htm
2019-02-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1107421/000093247119004638/0000932471-19-004638-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1107421/000108514619000809/0001085146-19-000809-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1107421/000108514620000816/0001085146-20-000816-index.htm
2020-01-30SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1107421/000110465920008766/0001104659-20-008766-index.htm
2020-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1107421/000110465920016345/0001104659-20-016345-index.htm
2018-11-19DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000110742118000001/0001107421-18-000001-index.htm
2019-08-09DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000110742119000001/0001107421-19-000001-index.htm
2019-09-17DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000110742119000002/0001107421-19-000002-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1107421/000112329220000273/0001123292-20-000273-index.htm
2018-10-15SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1107421/000114036118040642/0001140361-18-040642-index.htm
2018-12-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1107421/000114036118044998/0001140361-18-044998-index.htm
2018-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312518281213/0001193125-18-281213-index.htm
2018-10-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312518295299/0001193125-18-295299-index.htm
2018-10-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312518297307/0001193125-18-297307-index.htm
2018-10-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312518300286/0001193125-18-300286-index.htm
2018-11-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1107421/000119312518323155/0001193125-18-323155-index.htm
2018-11-09S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1107421/000119312518323181/0001193125-18-323181-index.htm
2018-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312518324941/0001193125-18-324941-index.htm
2018-11-28SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1107421/000119312518335464/0001193125-18-335464-index.htm
2018-12-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312518349457/0001193125-18-349457-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312519003789/0001193125-19-003789-index.htm
2019-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312519005769/0001193125-19-005769-index.htm
2019-02-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312519027041/0001193125-19-027041-index.htm
2019-02-07S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1107421/000119312519030904/0001193125-19-030904-index.htm
2019-02-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1107421/000119312519044283/0001193125-19-044283-index.htm
2019-02-22424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1107421/000119312519047677/0001193125-19-047677-index.htm
2019-03-0510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1107421/000119312519063978/0001193125-19-063978-index.htm
2019-03-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312519064031/0001193125-19-064031-index.htm
2019-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1107421/000119312519125377/0001193125-19-125377-index.htm
2019-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1107421/000119312519125403/0001193125-19-125403-index.htm
2019-04-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312519125434/0001193125-19-125434-index.htm
2019-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1107421/000119312519141382/0001193125-19-141382-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312519141405/0001193125-19-141405-index.htm
2019-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312519158352/0001193125-19-158352-index.htm
2019-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312519174799/0001193125-19-174799-index.htm
2019-06-21S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuershttps://www.sec.gov/Archives/edgar/data/1107421/000119312519178981/0001193125-19-178981-index.htm
2019-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312519181946/0001193125-19-181946-index.htm
2019-06-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312519184358/0001193125-19-184358-index.htm
2019-07-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312519188723/0001193125-19-188723-index.htm
2019-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312519200629/0001193125-19-200629-index.htm
2019-08-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312519210934/0001193125-19-210934-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1107421/000119312519216056/0001193125-19-216056-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312519216079/0001193125-19-216079-index.htm
2019-09-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312519244495/0001193125-19-244495-index.htm
2019-09-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312519255309/0001193125-19-255309-index.htm
2019-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312519259378/0001193125-19-259378-index.htm
2019-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312519267297/0001193125-19-267297-index.htm
2019-10-23424B7Prospectus [Rule 424(b)(7)]https://www.sec.gov/Archives/edgar/data/1107421/000119312519272608/0001193125-19-272608-index.htm
2019-10-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312519275559/0001193125-19-275559-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1107421/000119312519287259/0001193125-19-287259-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312519287298/0001193125-19-287298-index.htm
2019-11-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312519299251/0001193125-19-299251-index.htm
2020-01-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312520007174/0001193125-20-007174-index.htm
2020-02-04424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1107421/000119312520024354/0001193125-20-024354-index.htm
2020-02-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312520024518/0001193125-20-024518-index.htm
2020-02-05424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1107421/000119312520025491/0001193125-20-025491-index.htm
2020-02-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312520026318/0001193125-20-026318-index.htm
2020-03-0210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1107421/000119312520058863/0001193125-20-058863-index.htm
2020-03-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312520058964/0001193125-20-058964-index.htm
2020-04-2910-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1107421/000119312520126370/0001193125-20-126370-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1107421/000119312520136200/0001193125-20-136200-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312520136234/0001193125-20-136234-index.htm
2020-05-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1107421/000119312520136509/0001193125-20-136509-index.htm
2020-05-08PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1107421/000119312520137017/0001193125-20-137017-index.htm
2020-05-18DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1107421/000119312520145086/0001193125-20-145086-index.htm
2020-05-18DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1107421/000119312520145101/0001193125-20-145101-index.htm
2020-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312520155032/0001193125-20-155032-index.htm
2020-07-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312520184639/0001193125-20-184639-index.htm
2020-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312520198249/0001193125-20-198249-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1107421/000119312520211865/0001193125-20-211865-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312520211899/0001193125-20-211899-index.htm
2020-08-06S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1107421/000119312520212035/0001193125-20-212035-index.htm
2020-09-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312520250711/0001193125-20-250711-index.htm
2020-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312520260571/0001193125-20-260571-index.htm
2020-10-16DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1107421/000119312520271219/0001193125-20-271219-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1107421/000119312520286807/0001193125-20-286807-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1107421/000119312520286826/0001193125-20-286826-index.htm
2018-09-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919118051782/0001209191-18-051782-index.htm
2018-09-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919118051783/0001209191-18-051783-index.htm
2018-09-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919118051784/0001209191-18-051784-index.htm
2018-09-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919118051785/0001209191-18-051785-index.htm
2018-09-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919118051786/0001209191-18-051786-index.htm
2019-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919119000584/0001209191-19-000584-index.htm
2019-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919119000585/0001209191-19-000585-index.htm
2019-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919119000586/0001209191-19-000586-index.htm
2019-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919119000587/0001209191-19-000587-index.htm
2019-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919119000588/0001209191-19-000588-index.htm
2019-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919119000589/0001209191-19-000589-index.htm
2019-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919119000590/0001209191-19-000590-index.htm
2019-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919119002774/0001209191-19-002774-index.htm
2019-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919119002778/0001209191-19-002778-index.htm
2019-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919119002782/0001209191-19-002782-index.htm
2019-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919119002787/0001209191-19-002787-index.htm
2019-05-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919119028239/0001209191-19-028239-index.htm
2019-06-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919119037398/0001209191-19-037398-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919119037401/0001209191-19-037401-index.htm
2019-06-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919119038780/0001209191-19-038780-index.htm
2019-06-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919119038784/0001209191-19-038784-index.htm
2019-07-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919119042992/0001209191-19-042992-index.htm
2019-07-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919119042993/0001209191-19-042993-index.htm
2019-10-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919119053160/0001209191-19-053160-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919119054401/0001209191-19-054401-index.htm
2019-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919119058365/0001209191-19-058365-index.htm
2019-12-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919119062290/0001209191-19-062290-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919120001164/0001209191-20-001164-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919120001165/0001209191-20-001165-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919120001167/0001209191-20-001167-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919120001170/0001209191-20-001170-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919120001171/0001209191-20-001171-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919120001173/0001209191-20-001173-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919120001175/0001209191-20-001175-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919120001176/0001209191-20-001176-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919120001180/0001209191-20-001180-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919120001183/0001209191-20-001183-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919120001186/0001209191-20-001186-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919120005778/0001209191-20-005778-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919120005780/0001209191-20-005780-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919120005781/0001209191-20-005781-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919120005783/0001209191-20-005783-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919120005785/0001209191-20-005785-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919120005787/0001209191-20-005787-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919120005789/0001209191-20-005789-index.htm
2020-07-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919120043319/0001209191-20-043319-index.htm
2020-07-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919120043323/0001209191-20-043323-index.htm
2020-09-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919120052214/0001209191-20-052214-index.htm
2020-10-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000120919120054667/0001209191-20-054667-index.htm
2020-10-21PREC14APreliminary proxy statements, contested solicitationshttps://www.sec.gov/Archives/edgar/data/1107421/000121390020032558/0001213900-20-032558-index.htm
2020-10-27PRER14APreliminary Proxy Soliciting materialshttps://www.sec.gov/Archives/edgar/data/1107421/000121390020033544/0001213900-20-033544-index.htm
2020-11-02DEFC14ADefinitive proxy statement, contested solicitationshttps://www.sec.gov/Archives/edgar/data/1107421/000121390020034356/0001213900-20-034356-index.htm
2020-11-02DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1107421/000121390020034417/0001213900-20-034417-index.htm
2020-11-02DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1107421/000121390020034421/0001213900-20-034421-index.htm
2020-11-02DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1107421/000121390020034575/0001213900-20-034575-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1107421/000131586319000149/0001315863-19-000149-index.htm
2018-09-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000156761918003286/0001567619-18-003286-index.htm
2018-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1107421/000156761918003898/0001567619-18-003898-index.htm
2018-11-21SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1107421/000156761918006847/0001567619-18-006847-index.htm
2020-02-24SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1107421/000180435020000001/0001804350-20-000001-index.htm
2019-02-21EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1107421/999999999519000311/9999999995-19-000311-index.htm
2018-11-19CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1107421/999999999718009023/9999999997-18-009023-index.htm

ZIOPHARM Oncology, Inc (ZIOP) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of ZIOPHARM Oncology, Inc (ZIOP). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 656%
Institutional Ownership: 5519%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-01-02Robert HadfieldGeneral Counsel and SecretarySell16,853.004.5576,681.15100,719.00https://www.sec.gov/Archives/edgar/data/1107421/000120919120001173/0001209191-20-001173-index.htm
2019-12-31Elan EzicksonDirectorBuy31,780.00111,994.00https://www.sec.gov/Archives/edgar/data/1107421/000120919120001171/0001209191-20-001171-index.htm
2019-01-06Robert HadfieldGeneral Counsel and SecretaryBuy117,572.00117,572.00https://www.sec.gov/Archives/edgar/data/1107421/000120919119002782/0001209191-19-002782-index.htm
2019-01-06Laurence James Neil CooperChief Executive OfficerBuy337,266.001,518,075.00https://www.sec.gov/Archives/edgar/data/1107421/000120919119002778/0001209191-19-002778-index.htm
2020-01-29Robert HadfieldGeneral Counsel and SecretaryBuy59,100.00159,819.00https://www.sec.gov/Archives/edgar/data/1107421/000120919120005783/0001209191-20-005783-index.htm
2019-12-30Laurence James Neil CooperChief Executive OfficerSell110,694.004.88540,186.721,733,273.00https://www.sec.gov/Archives/edgar/data/1107421/000120919119062290/0001209191-19-062290-index.htm
2020-01-02Jill BuckEVP, GM Gene TherapySell27,923.004.55127,049.65173,710.00https://www.sec.gov/Archives/edgar/data/1107421/000120919120001167/0001209191-20-001167-index.htm
2020-01-02Groot Eleanor DeEVP, GM Cell TherapySell24,890.004.55113,249.50174,333.00https://www.sec.gov/Archives/edgar/data/1107421/000120919120001170/0001209191-20-001170-index.htm
2019-12-27Laurence James Neil CooperChief Executive OfficerBuy44,642.002.2499,998.081,843,967.00https://www.sec.gov/Archives/edgar/data/1107421/000120919119062290/0001209191-19-062290-index.htm
2020-01-29Laurence James Neil CooperChief Executive OfficerBuy171,700.001,904,973.00https://www.sec.gov/Archives/edgar/data/1107421/000120919120005780/0001209191-20-005780-index.htm
2020-01-02DAVID M MD MAUNEYPresidentSell22,394.004.55101,892.70195,278.00https://www.sec.gov/Archives/edgar/data/1107421/000120919120001180/0001209191-20-001180-index.htm
2019-01-06Laurence James Neil CooperChief Executive OfficerBuy446,428.001,964,503.00https://www.sec.gov/Archives/edgar/data/1107421/000120919119002778/0001209191-19-002778-index.htm
2019-01-06DAVID M MD MAUNEYPresidentBuy159,010.00217,672.00https://www.sec.gov/Archives/edgar/data/1107421/000120919119002774/0001209191-19-002774-index.htm
2020-01-29Jill BuckEVP, GM Gene TherapyBuy53,700.00227,410.00https://www.sec.gov/Archives/edgar/data/1107421/000120919120005778/0001209191-20-005778-index.htm
2020-01-29Groot Eleanor DeEVP, GM Cell TherapyBuy53,700.00228,033.00https://www.sec.gov/Archives/edgar/data/1107421/000120919120005781/0001209191-20-005781-index.htm
2020-01-29DAVID M MD MAUNEYPresidentBuy80,500.00275,778.00https://www.sec.gov/Archives/edgar/data/1107421/000120919120005787/0001209191-20-005787-index.htm
2019-12-31Scott BraunsteinDirectorBuy31,780.0031,780.00https://www.sec.gov/Archives/edgar/data/1107421/000120919120001165/0001209191-20-001165-index.htm
2019-12-31Heidi HagenDirectorBuy31,780.0032,119.00https://www.sec.gov/Archives/edgar/data/1107421/000120919120001175/0001209191-20-001175-index.htm
2019-05-07JAMES ANTHONY CANNONDirectorBuy15,000.000.7010,500.00398,050.00https://www.sec.gov/Archives/edgar/data/1107421/000120919119028239/0001209191-19-028239-index.htm
2018-12-31Douglas W. PaganDirectorBuy40,107.0040,107.00https://www.sec.gov/Archives/edgar/data/1107421/000120919119000589/0001209191-19-000589-index.htm
2019-12-31Douglas W. PaganDirectorBuy15,890.0055,997.00https://www.sec.gov/Archives/edgar/data/1107421/000120919120001183/0001209191-20-001183-index.htm
2020-01-02Kevin G LafondSVP, Treasurer & CAOSell21,570.004.5598,143.5063,985.00https://www.sec.gov/Archives/edgar/data/1107421/000120919120001176/0001209191-20-001176-index.htm
2018-12-31Elan EzicksonDirectorBuy80,214.0080,214.00https://www.sec.gov/Archives/edgar/data/1107421/000120919119000587/0001209191-19-000587-index.htm
2020-01-29Sath ShuklaEVP, Chief Financial OfficerBuy80,500.0080,500.00https://www.sec.gov/Archives/edgar/data/1107421/000120919120005789/0001209191-20-005789-index.htm
2020-01-29Kevin G LafondSVP, Treasurer & CAOBuy18,000.0081,985.00https://www.sec.gov/Archives/edgar/data/1107421/000120919120005785/0001209191-20-005785-index.htm
2019-01-06Kevin G LafondSVP, Treasurer & CAOBuy37,122.0085,555.00https://www.sec.gov/Archives/edgar/data/1107421/000120919119002787/0001209191-19-002787-index.htm
2019-11-26Kevin G LafondSVP, Treasurer & CAOSell11,667.005.2561,251.7585,555.00https://www.sec.gov/Archives/edgar/data/1107421/000120919119058365/0001209191-19-058365-index.htm
2019-11-26Kevin G LafondSVP, Treasurer & CAOBuy11,667.002.8533,250.9597,222.00https://www.sec.gov/Archives/edgar/data/1107421/000120919119058365/0001209191-19-058365-index.htm